Treatment with Phps-1, which inhibits a protein called Shp2, was able to alleviate specific symptoms of pulmonary arterial hypertension (PAH) in a rat model, suggesting that Shp2 may be a potential therapeutic target for PAH treatment, a study reports. The study, “Inhibition of Shp2 ameliorates monocrotaline-induced…
News
The U.S. Food and Drug Administration has granted orphan drug designation to Livantra, a new formulation of an already approved treatment outside the U.S. for another indication, for the treatment of pulmonary arterial hypertension (PAH), according to the…
Inhibition of proteins that regulate gene expression — called BET — were found to ease pulmonary hypertension (PH) in a rat model of chronic obstructive pulmonary disease (COPD), a study reports. The study, “Inhibition of BET Proteins Reduces Right Ventricle Hypertrophy and Pulmonary Hypertension Resulting from Combined…
A clinical trial to study a therapy that may inhibit and possibly reverse vascular remodeling in pulmonary arterial hypertension (PAH) is expected to start enrolling patients in 2019. The medicine, C76, was shown to inhibit a gene called HIF-2α and to lead to reversal of PAH in animal models. The study…
Research & DevelopmentTreatment with the approved anti-cancer medication sorafenib reversed pulmonary arterial hypertension (PAH) and cardiopulmonary remodeling (CPR) in a rat model, according to a new study. The findings suggest that a low-dose therapy with this compound may be successful in PAH treatment, the Japanese research team suggests.
A man with pulmonary hypertension, the first international patient to receive an advanced but totally artificial heart known as the CARMAT heart, recently had a healthy donor heart successfully transplanted. The announcement, made by the National Research Center for Cardiac Surgery, in Astana, Kazakhstan, was confirmed by…
Bellerophon Therapeutics recently provided an update on the clinical development of INOpulse as a treatment for pulmonary arterial hypertension (PAH), as well as for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and interstitial lung disease (PH-ILD). INOpulse is an inhaled nitric oxide treatment being developed to reduce…
Estimated survival in patients with either pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) is worse if they also have atrial arrhythmias, according to a new U.S. study. The study, “Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension,” was published…
The emotional well-being of people with pulmonary hypertension (PH), particularly in relation to levels of anxiety and depression, may be better explained by taking into account their life circumstances and not the severity of their disease alone, a study reports. The study, “Depression and Anxiety in Patients With Pulmonary…
The U.S. Food and Drug Administration has approved Medtronic’s Implantable System for Remodulin, or ISR, to deliver Remodulin to patients with pulmonary arterial hypertension (PAH). PAH patients have high blood pressure in their pulmonary arteries, those that carry blood from the heart to the lungs, which can cause damage to…
Patients with pulmonary hypertension have little daily exercise, often at levels so low their their odds of survival are reduced, according to researchers. Their study, “Physical activity levels are low in patients with pulmonary hypertension,” was published in the journal Annals of Translational Medicine. International guidelines recommend…
SOX17 may be a risk gene that contributes to pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD), as well as to idiopathic and/or familial PAH, according to researchers. Their study, “Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital…
